In vivo, PPARγ agonists such as lanifibranor and curcumin act by activating the PPARγ pathway to inhibit pulmonary fibrosis induced by bleomycin (BLM), SiO2, or paraquat [24,25,26,27,28]. Here, PPARG is linked to pulmonary fibrosis.